Biomarin Pharmaceutical Inc. (BM8)
XHAN
Closed
Aug 21, 2026
Day's Range
57.7452 wk Range
42.55Overview - BM8 - Biomarin Pharmaceutical Inc.
Key Statistics
Valuation
Enterprise Value
-705.81M
P/E (Trailing)
‪31.80‬
PEG Ratio
‪-0.38‬
Price / Book
‪1.77‬
EV / EBITDA
‪-1.23‬
Profitability
Gross Margin
‪79.50%‬
Profit Margin
‪77.72%‬
Operating Margin
‪15.31%‬
Return on Assets
‪4.59%‬
Return on Equity
‪5.73%‬
Ownership
Shares Outstanding
193.28M
Price stats
50-Day Avg
‪52.61‬
200-Day Avg
‪49.27‬
Peers - BM8 - Biomarin Pharmaceutical Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XHAN.
- BM8XHANBiomarin Pharmaceutical Inc.+14.63%52-week change31.80P/E (Trailing)‪77.72%‬Profit Margin
- 0QFXHANModerna, Inc.+82.89%52-week change-17.84P/E (Trailing)‪54.83%‬Profit Margin
- 1AEAXHANargenx SE American Depositary Receipt+34.08%52-week change42.46P/E (Trailing)‪89.14%‬Profit Margin
- ANLXHANAnalog Devices, Inc.+32.46%52-week change69.63P/E (Trailing)‪61.46%‬Profit Margin
- 22UAXHANBioNTech SE+8.98%52-week change-21.20P/E (Trailing)‪77.63%‬Profit Margin
- BBZAXHANBB Biotech AG+0.00%52-week change5.58P/E (Trailing)—Profit Margin
- ANTHXHANBrw Stable Return Fund-2.88%52-week change—P/E (Trailing)—Profit Margin
Profile Summary - BM8 - Biomarin Pharmaceutical Inc.
About
BioMarin Pharmaceutical Inc. is a leading global biotechnology company specializing in the development and commercialization of therapies for people with serious and life-threatening rare genetic diseases. Its portfolio includes eight approved treatments targeting conditions such as mucopolysaccharidosis types I, IVA,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
